Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
61
datasets available to search
ShareScore release 0.9.0
Dataset results
61 results for “PCSK9 inhibitors”
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy reduces the level of DNA damage in patients with heterozygous familial hypercholesterolemia
<p><span><span>Heterozygous Familial Hypercholesterolaemia (HeFH) is a common autosomal dominant genetic disease (1:300) characterized by elevated LDL-C leading to premature atherosclerosis. Treatment with a PCSK9 inhibitor (iPCSK9) is recommended in high cardiovascular risk FH patients if the treatment goal is not achieved on maximal tolerated statin plus ezetimibe. </span></span><span>The aim of this study was to </span><span><span>examine the changes in DNA damage in HeFH patients associated with iPCSK9 use. </span></span><span>Fifty-seven patients were included: a normolipidemic group (control; n=20) and patients with HeFH (study group; n=36). DNA damage was determined by alkaline comet assay. PCSK9 protein level was assessed by ELISA. </span><span>The levels of Lp(a) in human serum were quantitatively turbidimetrically assay.</span><span> </span><span>PCSK9i treatment was associated with lower DNA damage, Lp(a), PCSK9 and lipid profile than before treatment. However, 20 of 36 patients still had Lp(a) values above 125 nmol/L, and reduced Lp(a) did not correlate with reduced DNA damage. Reduced PCSK9 moderately (r=0.48) correlates with reduced DNA damage</span><span><span>. PCSK9i therapy reduces the level of DNA damage in HeFH patients, regardless of the type of inhibitor. The reduction in DNA damage is not related to the changes in lipid profile or Lp(a) induced by PCSK9i, but it is dependent on PCSK9 level.</span></span></p>
A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
ClinicalTrials.gov study NCT05261126. IPD Sharing: YES. Countries: 8. Publications: 1.
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholes
ClinicalTrials.gov study NCT06450366. IPD Sharing: YES. Countries: 8. Publications: 0.
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH
ClinicalTrials.gov study NCT05952869. IPD Sharing: YES. Countries: 17. Publications: 1.
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
ClinicalTrials.gov study NCT03193047. IPD Sharing: NO. Countries: 1. Publications: 4.
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
ClinicalTrials.gov study NCT06902740. IPD Sharing: UNDECIDED. Countries: 1. Publications: 13.
COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients
ClinicalTrials.gov study NCT03139630. IPD Sharing: NO. Countries: 1. Publications: 1.
Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction
ClinicalTrials.gov study NCT05292404. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)
ClinicalTrials.gov study NCT06730802. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
ClinicalTrials.gov study NCT06933251. IPD Sharing: NO. Countries: 1. Publications: 2.
Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis
ClinicalTrials.gov study NCT04968509. IPD Sharing: NO. Countries: 1. Publications: 14.
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
ClinicalTrials.gov study NCT06304987. IPD Sharing: NO. Countries: 1. Publications: 4.
Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography
ClinicalTrials.gov study NCT04338165. IPD Sharing: NO. Countries: 1. Publications: 22.
Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study
ClinicalTrials.gov study NCT07084259. IPD Sharing: YES. Countries: 0. Publications: 0.
Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography
ClinicalTrials.gov study NCT06863545. IPD Sharing: YES. Countries: 2. Publications: 14.
Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study
ClinicalTrials.gov study NCT04730648. IPD Sharing: Not stated. Countries: 1. Publications: 1.
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
ClinicalTrials.gov study NCT05553834. IPD Sharing: NO. Countries: 1. Publications: 0.
Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography
ClinicalTrials.gov study NCT04851769. IPD Sharing: NO. Countries: 1. Publications: 2.
Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography
ClinicalTrials.gov study NCT06520904. IPD Sharing: NO. Countries: 1. Publications: 14.
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
ClinicalTrials.gov study NCT05952856. IPD Sharing: YES. Countries: 14. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.